Alexo Therapeutics

Alexo Therapeutics is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.

The founding of Alexo Therapeutics was based upon technology invented by Aaron Ring, K. Christopher Garcia, Kipp Weiskopf, Aron Levin, and Irving Weissman at Stanford University. This discovery involves soluble versions of signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα.1 Alexo is an independent, private biotechnology company. They closed their Series A funding of $36M in May 2015, which was led by venBio and joined by Lightstone Ventures, the Longevity Fund, and Stanford University. Dr. Corey Goodman is their Chair and Dr. Jaume Pons their President and CEO. Their growing R&D team is located in South San Francisco.